We have previously shown a functional motor interaction between ethanol and Δ9-tetrahydrocannabinol (Δ9-THC) that involved cerebellar adenosinergic A1 and GABAergic A receptor modulation. We now report the development of cross-tolerance between intracerebellar Δ9-THC and intraperitoneal ethanol using ataxia as the test response in male CD-1 mice. The drugs [Δ9-THC (20μg), N6-cyclohexyladenosine, CHA (12ng), muscimol (20ng)] used in the study were directly microinfused stereotaxically via guide cannulas into the cerebellum except ethanol. Δ9-THC, infused once daily for 5 days followed 16h after the last infusion by acute ethanol (2g/kg) and Rotorod evaluation, virtually abolished ethanol ataxia indicating development of cross-tolerance. The cross-tolerance was also observed when the order of ethanol and Δ9-THC treatment was reversed, i.e., ethanol injected once daily for 5 days followed 16h after the last ethanol injection by Δ9-THC infusion. The cross-tolerance appeared within 24–48h, lasted over 72h and was maximal in 5-day ethanol/Δ9-THC-treated animals. Finally, tolerance in chronic ethanol/Δ9-THC/-treated animals developed not only to ethanol/Δ9-THC-induced ataxia, respectively, but also to the ataxia potentiating effect of CHA and muscimol, indicating modulation by cerebellar adenosinergic A1 and GABAA receptors. A practical implication of these results could be that marijuana smokers may experience little or no negative effects such as ataxia following alcohol consumption. Clinically, such antagonism of ethanol-induced ataxia can be observed in marijuana users thereby encouraging more alcohol consumption and thus may represent a risk factor for the development of alcoholism in this segment of population.